About 8 results found for searched term "BET bromodomain inhibitor 3" (0.138 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41661 | BET bromodomain inhibitor 3 | Epigenetic Reader Domain |
| BET bromodomain inhibitor 3 is BET bromodomain inhibitor. | ||
| M2167 | (+)-JQ1 | Epigenetic Reader Domain |
| JQ1 | ||
| (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway. | ||
| M2903 | OTX015 (Birabresib) | Epigenetic Reader Domain |
| MK-8628; Birabresib | ||
| OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. | ||
| M3526 | CPI-203 | Epigenetic Reader Domain |
| CPI203 | ||
| CPI-203 is a novel potent, selective BET bromodomain inhibitor with IC50 of 37 nM for BRD4. | ||
| M13825 | Molibresib besylate | Epigenetic Reader Domain |
| GSK 525762C; I-BET 762 besylate | ||
| Molibresib besylate (GSK 525762C; I-BET 762 besylate) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM. | ||
| M27706 | RVX-297 | Epigenetic Reader Domain |
| RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2. RVX-297 shows IC50s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models. | ||
| M28741 | GS-626510 | Epigenetic Reader Domain |
| GS-626510 is a potent, and orally active BET family bromodomains inhibitor, with Kd values of 0.59-3.2 nM for BRD2/3/4, with IC50 values of 83 nM and 78 nM foe BD1 and BD2, respectively. | ||
| M29257 | NHWD-870 | Epigenetic Reader Domain |
| NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
